Melanoma Research Today is a free monthly online journal that collates and summarizes the latest research about Melanoma, including details on identification, causes, prevention, treatment.

Volume 4 (2007), Issue 4 (April)

1. Genetic study of familial uveal melanoma: association of uveal and cutaneous melanoma with cutaneous and ocular nevi.
   Ophthalmology, 114(4): 774-9. [Abstract] [Full-text]
2. Histological study of choroidal malignant melanoma treated by carbon ion radiotherapy.
   Jpn J Ophthalmol, 51(2): 127-30. [Abstract] [Full-text]
3. The association between residential pesticide use and cutaneous melanoma.
   Eur J Cancer, 43(6): 1066-75. [Abstract] [Full-text]
4. Preclinical studies of carbohydrate mimetic peptide vaccines for breast cancer and melanoma.
   Vaccine, 25(16): 3022-31. [Abstract] [Full-text]
5. The increased expression of Y box-binding protein 1 in melanoma stimulates proliferation and tumor invasion, antagonizes apoptosis and enhances chemoresistance.
   Int J Cancer, 120(10): 2110-8. [Abstract] [Full-text]
6. Trichostatin A and 5-aza-2'-deoxycytidine switch S1P from an inhibitor to a stimulator of motility through epigenetic regulation of S1P receptors.
   Cancer Lett, 250(1): 53-62. [Abstract] [Full-text]
7. Objective and subjective stressors and the psychological adjustment of melanoma survivors.
   Psychooncology, 16(4): 287-94. [Abstract] [Full-text]
8. c-Met is a potentially new therapeutic target for treatment of human melanoma.
   Clin Cancer Res, 13(7): 2246-53. [Abstract] [Full-text]
9. Effects of the administration of high-dose interleukin-2 on immunoregulatory cell subsets in patients with advanced melanoma and renal cell cancer.
   Clin Cancer Res, 13(7): 2100-8. [Abstract] [Full-text]
10. Utility of circulating B-RAF DNA mutation in serum for monitoring melanoma patients receiving biochemotherapy.
    Clin Cancer Res, 13(7): 2068-74. [Abstract] [Full-text]
11. Fluctuating and diffusion-limited hypoxia in hypoxia-induced metastasis.
    Clin Cancer Res, 13(7): 1971-8. [Abstract] [Full-text]
12. Mannan-modified adenovirus as a vaccine to induce antitumor immunity.
    Gene Ther, 14(8): 657-63. [Abstract] [Full-text]
13. Melanomas require HEDGEHOG-GLI signaling regulated by interactions between GLI1 and the RAS-MEK/AKT pathways.
    Proc Natl Acad Sci U S A, 104(14): 5895-900. [Abstract] [Full-text]
14. Multiple mechanisms underlie defective recognition of melanoma cells cultured in three-dimensional architectures by antigen-specific cytotoxic T lymphocytes.
    Br J Cancer, 96(7): 1072-82. [Abstract] [Full-text]
15. Detection of mutated BRAFV600E variant in circulating DNA of stage III-IV melanoma patients.
    Int J Cancer, 120(11): 2439-44. [Abstract] [Full-text]
16. Intratumoral injection of dendritic cells in combination with local hyperthermia induces systemic antitumor effect in patients with advanced melanoma.
    Int J Cancer, 120(11): 2418-25. [Abstract] [Full-text]
17. A high-throughput study in melanoma identifies epithelial-mesenchymal transition as a major determinant of metastasis.
    Cancer Res, 67(7): 3450-60. [Abstract] [Full-text]
18. Mutant V600E BRAF increases hypoxia inducible factor-1alpha expression in melanoma.
    Cancer Res, 67(7): 3177-84. [Abstract] [Full-text]
19. Systemic targeting inhibitor of kappaB kinase inhibits melanoma tumor growth.
    Cancer Res, 67(7): 3127-34. [Abstract] [Full-text]
20. RaLP, a new member of the Src homology and collagen family, regulates cell migration and tumor growth of metastatic melanomas.
    Cancer Res, 67(7): 3064-73. [Abstract] [Full-text]
21. Transverse twist flap for lip reconstruction in patient with lentigo maligna of the labial mucosa.
    J Dermatol, 34(5): 333-5. [Abstract] [Full-text]
22. Bovine pericardium (Tutopatch) wrap for hydroxyapatite implants.
    Eye, 21(4): 476-9. [Abstract] [Full-text]
23. Long-term results of hyperthermic, isolated limb perfusion for melanoma: a reflection of tumor biology.
    Ann Surg, 245(4): 591-6. [Abstract] [Full-text]
24. A metastatic melanoma with an unusual immunophenotypic profile.
    Am J Dermatopathol, 29(2): 169-71. [Abstract] [Full-text]
25. Pretreatment levels of sTNF-R1 and sIL-6R are associated with a higher vulnerability for IFN-alpha-induced depressive symptoms in patients with malignant melanoma.
    J Immunother (1997), 30(3): 333-7. [Abstract] [Full-text]
26. CDKN2A (INK4A-ARF) mutation analysis to distinguish cutaneous melanoma metastasis from a second primary melanoma.
    Am J Surg Pathol, 31(4): 637-41. [Abstract] [Full-text]
27. Melanoma in children and teenagers: an analysis of patients from the National Cancer Data Base.
    J Clin Oncol, 25(11): 1363-8. [Abstract] [Full-text]
28. Diacylglycerol kinase alpha suppresses tumor necrosis factor-alpha-induced apoptosis of human melanoma cells through NF-kappaB activation.
    Biochim Biophys Acta, 1771(4): 462-74. [Abstract] [Full-text]
29. Cell surface chondroitin sulfate glycosaminoglycan in melanoma: role in the activation of pro-MMP-2 (pro-gelatinase A).
    Biochem J, 403(3): 553-63. [Abstract] [Full-text]
30. Proteomics in uveal melanoma research: opportunities and challenges in biomarker discovery.
    Expert Rev Proteomics, 4(2): 273-86. [Abstract] [Full-text]
31. Loss of smooth muscle calponin results in impaired blood vessel maturation in the tumor-host microenvironment.
    Cancer Sci, 98(5): 757-63. [Abstract] [Full-text]
32. Fibroblast growth factor-2-induced host stroma reaction during initial tumor growth promotes progression of mouse melanoma via vascular endothelial growth factor A-dependent neovascularization.
    Cancer Sci, 98(4): 541-8. [Abstract] [Full-text]
33. Overexpression of caveolin-1 in a human melanoma cell line results in dispersion of ganglioside GD3 from lipid rafts and alteration of leading edges, leading to attenuation of malignant properties.
    Cancer Sci, 98(4): 512-20. [Abstract] [Full-text]
34. NRAGE suppresses metastasis of melanoma and pancreatic cancer in vitro and in vivo.
    Cancer Lett, 250(2): 268-75. [Abstract] [Full-text]
35. Mohs surgery for the treatment of melanoma in situ: a review.
    Dermatol Surg, 33(4): 395-402. [Abstract] [Full-text]
36. Sentinel node staging of primary melanoma by the "10% rule": pathology and clinical outcomes.
    Am J Surg, 193(5): 618-22; discussion 622. [Abstract] [Full-text]
37. Eruptive latent metastatic melanomas after initiation of antitumor necrosis factor therapies.
    J Am Acad Dermatol, 56(5): S65-7. [Abstract] [Full-text]
38. CDKN2A germline mutations in individuals with cutaneous malignant melanoma.
    J Invest Dermatol, 127(5): 1234-43. [Abstract] [Full-text]
39. Protective effect of hyperpigmented skin on UV-mediated cutaneous cancer development.
    J Invest Dermatol, 127(5): 1244-9. [Abstract] [Full-text]
40. Multiple melanomas after treatment for Hodgkin lymphoma in a non-Dutch p16-Leiden mutation carrier with 2 MC1R high-risk variants.
    Arch Dermatol, 143(4): 495-9. [Abstract] [Full-text]
41. Melanoma outcomes for Medicare patients: association of stage and survival with detection by a dermatologist vs a nondermatologist.
    Arch Dermatol, 143(4): 488-94. [Abstract] [Full-text]
42. Cell cycle and apoptosis regulators in Spitz nevi: comparison with melanomas and common nevi.
    J Am Acad Dermatol, 56(5): 815-24. [Abstract] [Full-text]
43. Nail matrix biopsy of longitudinal melanonychia: diagnostic algorithm including the matrix shave biopsy.
    J Am Acad Dermatol, 56(5): 803-10. [Abstract] [Full-text]
44. Primary mucosal melanoma.
    J Am Acad Dermatol, 56(5): 828-34. [Abstract] [Full-text]
45. Association between the anatomic distribution of melanoma and sex.
    J Am Acad Dermatol, 56(5): 768-73. [Abstract] [Full-text]
46. Sensitivity, specificity, and diagnostic accuracy of three dermoscopic algorithmic methods in the diagnosis of doubtful melanocytic lesions: the importance of light brown structureless areas in differentiating atypical melanocytic nevi from thin melanomas.
    J Am Acad Dermatol, 56(5): 759-67. [Abstract] [Full-text]
47. Depletion of CD4+CD25+ human regulatory T cells in vivo: kinetics of Treg depletion and alterations in immune functions in vivo and in vitro.
    Int J Cancer, 120(12): 2723-33. [Abstract] [Full-text]
48. Profiles of chemokine receptors in melanocytic lesions: de novo expression of CXCR6 in melanoma.
    Hum Pathol, 38(5): 768-80. [Abstract] [Full-text]
49. Phosphorylation of ectopically expressed L-plastin enhances invasiveness of human melanoma cells.
    Int J Cancer, 120(12): 2590-9. [Abstract] [Full-text]
50. Treatment of extensive cutaneous metastatic melanoma with topical diphencyprone.
    J Am Acad Dermatol, 56(5): 869-71. [Abstract] [Full-text]
51. From sporadic atypical nevi to familial melanoma: risk analysis for melanoma in sporadic atypical nevus patients.
    J Am Acad Dermatol, 56(5): 748-52. [Abstract] [Full-text]
52. Spitz nevus versus malignant melanoma: spitz nevi predominate on the thighs in patients younger than 40 years of age, melanomas on the trunk in patients 40 years of age or older.
    J Am Acad Dermatol, 56(5): 753-8. [Abstract] [Full-text]
53. Evaluation of prospectively collected presenting signs/symptoms of biopsy-proven melanoma, basal cell carcinoma, squamous cell carcinoma, and seborrheic keratosis in an elderly male population.
    J Am Acad Dermatol, 56(5): 739-47. [Abstract] [Full-text]
54. Multispectral imaging and artificial neural network: mimicking the management decision of the clinician facing pigmented skin lesions.
    Phys Med Biol, 52(9): 2599-613. [Abstract] [Full-text]
55. Characterization of a germ-line deletion, including the entire INK4/ARF locus, in a melanoma-neural system tumor family: identification of ANRIL, an antisense noncoding RNA whose expression coclusters with ARF.
    Cancer Res, 67(8): 3963-9. [Abstract] [Full-text]
56. Degrasyn activates proteasomal-dependent degradation of c-Myc.
    Cancer Res, 67(8): 3912-8. [Abstract] [Full-text]
57. PRAS40 deregulates apoptosis in malignant melanoma.
    Cancer Res, 67(8): 3626-36. [Abstract] [Full-text]
58. Shared MHC class II-dependent melanoma ribosomal protein L8 identified by phage display.
    Cancer Res, 67(8): 3555-9. [Abstract] [Full-text]
59. Novel somatic and germline mutations in cancer candidate genes in glioblastoma, melanoma, and pancreatic carcinoma.
    Cancer Res, 67(8): 3545-50. [Abstract] [Full-text]
60. Immunohistochemical evaluation of necrotic malignant melanomas.
    Am J Clin Pathol, 127(5): 787-91. [Abstract] [Full-text]
61. Toward a molecular classification of melanoma.
    J Clin Oncol, 25(12): 1606-20. [Abstract] [Full-text]
62. Sentinel lymph node molecular ultrastaging in patients with melanoma: a systematic review and meta-analysis of prognosis.
    J Clin Oncol, 25(12): 1588-95. [Abstract] [Full-text]
63. Pretreatment levels of peripheral neutrophils and leukocytes as independent predictors of overall survival in patients with American Joint Committee on Cancer Stage IV Melanoma: results of the EORTC 18951 Biochemotherapy Trial.
    J Clin Oncol, 25(12): 1562-9. [Abstract] [Full-text]
64. Melanoma, long wavelength ultraviolet and sunscreens: controversies and potential resolutions.
    Pharmacol Ther, 114(2): 198-207. [Abstract] [Full-text]
65. Punch biopsy of iris lesions: a novel technique for obtaining histology samples.
    Br J Ophthalmol, 91(5): 660-2. [Abstract] [Full-text]
66. Different mechanisms can lead to the same altered HLA class I phenotype in tumors.
    Tissue Antigens, 69: 259-63. [Abstract] [Full-text]
67. Fourier transform infrared imaging as a method for detection of HLA class I expression in melanoma without the use of antibody.
    Tissue Antigens, 69: 252-8. [Abstract] [Full-text]
68. HLA expression and cancer--14th IHIWS immunohistochemistry quality control exercise exchange results.
    Tissue Antigens, 69: 248-51. [Abstract] [Full-text]
69. Isolated metastatic melanoma to the gallbladder: is laparoscopic cholecystectomy indicated?: a case report and review of the literature.
    Surg Laparosc Endosc Percutan Tech, 17(2): 141-4. [Abstract] [Full-text]
70. Primary chondroid melanoma of the nasal skin: a rare melanoma variant at a previously undocumented site.
    J Cutan Pathol, 34(5): 427-30. [Abstract] [Full-text]
71. Aggressive osteogenic desmoplastic melanoma: a case report.
    J Cutan Pathol, 34(5): 423-6. [Abstract] [Full-text]
72. Melanoma associated with a dermatofibroma.
    J Cutan Pathol, 34(5): 420-2. [Abstract] [Full-text]
73. Displacement of dermal solar elastosis in malignant melanoma.
    J Cutan Pathol, 34(5): 376-80. [Abstract] [Full-text]
74. Nestin expression in cutaneous melanomas and melanocytic nevi.
    J Cutan Pathol, 34(5): 370-5. [Abstract] [Full-text]
75. Comparison of metallothionein-overexpression with sentinel lymph node biopsy as prognostic factors in melanoma.
    J Eur Acad Dermatol Venereol, 21(5): 669-77. [Abstract] [Full-text]
76. Role of tumor invasiveness, the extracellular matrix, and chromatin sequestration in the susceptibility of uveal melanoma to herpes simplex virus type 1.
    Exp Eye Res, 84(5): 991-1000. [Abstract] [Full-text]
77. Virosome-mediated delivery of tumor antigen to plasmacytoid dendritic cells.
    Vaccine, 25(19): 3913-21. [Abstract] [Full-text]
78. Recombinant IL-7 enhances the potency of GM-CSF-secreting tumor cell immunotherapy.
    Clin Immunol, 123(2): 155-65. [Abstract] [Full-text]
79. The N-terminal flanking region of the TRP2360-368 melanoma antigen determines proteasome activator PA28 requirement for epitope liberation.
    J Biol Chem, 282(17): 12749-54. [Abstract] [Full-text]
80. Angiotropic melanoma and extravascular migratory metastasis: a review.
    Adv Anat Pathol, 14(3): 195-201. [Abstract] [Full-text]
81. The spatial distribution of monosomy 3 and network vasculogenic mimicry patterns in uveal melanoma.
    Invest Ophthalmol Vis Sci, 48(5): 1918-22. [Abstract] [Full-text]
82. DNA repair gene polymorphisms and genetic predisposition to cutaneous melanoma.
    Carcinogenesis, 28(5): 1087-93. [Abstract] [Full-text]
83. Dendritic cell based antitumor vaccination: impact of functional indoleamine 2,3-dioxygenase expression.
    Cancer Immunol Immunother, 56(7): 1017-24. [Abstract] [Full-text]
84. Small numbers of residual tumor cells at the site of primary inoculation are critical for anti-tumor immunity following challenge at a secondary location.
    Cancer Immunol Immunother, 56(7): 1119-31. [Abstract] [Full-text]
85. Cross-talk between calpain and caspase-3/-7 in cisplatin-induced apoptosis of melanoma cells: a major role of calpain inhibition in cell death protection and p53 status.
    Oncogene, 26(19): 2717-26. [Abstract] [Full-text]
86. Is 2,3,5-pyrroletricarboxylic acid in hair a better risk indicator for melanoma than traditional epidemiologic measures for skin phenotype?
    Am J Epidemiol, 165(10): 1170-7. [Abstract] [Full-text]
87. Functional genomics of calcium channels in human melanoma cells.
    Int J Cancer, 121(1): 55-65. [Abstract] [Full-text]

© 2004-2008 Melanoma Research Today. All Rights Reserved.